Pharmaceutical Research

雜志介紹

Pharmaceutical Research雜志介紹

《Pharmaceutical Research》是一本以English為主的未開放獲取國際優秀期刊，中文名稱藥物研究，本刊主要出版、報道醫學-CHEMISTRY, MULTIDISCIPLINARY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為3.5，最新CiteScore 指數為6.6。

本刊近期中國學者發表的論文主要有：

• Exosomes as Carriers for Drug Delivery in Cancer Therapy

  Author: Zeng, Weiping; Wen, Zhengbo; Chen, Honglin; Duan, Yuyou

• Optimized Cationic Lipid-assisted Nanoparticle for Delivering CpG Oligodeoxynucleotides to Treat Hepatitis B Virus Infection

  Author: Chen, Yi-Fang; Wang, Yan; Wang, Yue; Luo, Ying-Li; Lu, Zi-Dong; Du, Xiao-Jiao; Xu, Cong-Fei; Wang, Jun

• Melt Crystallization of Celecoxib-Carbamazepine Cocrystals with the Synchronized Release of Drugs

  Author: Chen, An; Cai, Peishan; Luo, Minqian; Guo, Minshan; Cai, Ting

• Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy

  Author: Zhong, Jie; Wen, Weiye; Wang, Jinjin; Zhang, Mengyu; Jia, Yijiang; Ma, Xiaowei; Su, Yu-Xiong; Wang, Yuji; Lan, Xinmiao

英文介紹

Pharmaceutical Research雜志英文介紹

Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to:

-(pre)formulation engineering and processing-

computational biopharmaceutics-

drug delivery and targeting-

molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)-

pharmacokinetics, pharmacodynamics and pharmacogenetics.

Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.